201. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
- Author
-
Schäfer, E, Schlimok, G, Falge, C, Schmidt-Wolf, I, Schnittger, S, Staib, P, Kröger, N, Hochhaus, A, Scheid, C, Prümmer, O, Arnold, R, Haferlach, C, Spiekermann, K, Wehmeier, A, Th Fischer, J, Berger, U, Mayer, J, Kolb, H-J, Baerlocher, Gabriela M., Gratwohl, A, Reiter, A, Pfreundschuh, M, Hasford, J, Hertenstein, B, Schatz, M, Nerl, C, Bunjes, D, Fauser, A, Ho, A D, Beelen, D, Müller, M C, Rosselet, A, Wilhelm, M, Zander, A, Edinger, M, Hellmann, A, Sayer, H G, Goebeler, M-E, Hossfeld, D K, Novotny, J, Wulf, G, Büsche, G, Heimpel, H, Fabian, M, Pfirrmann, M, Baurmann, H, Ganser, A, Hehlmann, R, Aul, C, Schenk, M, Bormann, M, Schwerdtfeger, R, Kindler, T, Lindemann, H W, Döhner, H, Saußele, S, Schmitz, N, and Kuse, R
- Subjects
hemic and lymphatic diseases ,610 Medicine & health ,3. Good health - Abstract
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69-0.82) vs 0.69 (95% CI: 0.61-0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high- (P